A comprehensive meta-analysis evaluated the safety and efficacy of 15 GLP-1 RAs, including newer medications like orforglipron, retatrutide, and cagrisema, in individuals with T2DM. This evidence concerns the gene GCG and type 2 diabetes mellitus.